NeuroSense Therapeutics Ltd. — Proxy Solicitation & Information Statement 2025

Aug 21, 2025

6-K 1 ea025405001-6k_neuro.htm REPORT OF FOREIGN PRIVATE ISSUER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

_____

FORM 6-K

_____

Report of Foreign Private Issuer Pursuant to Rule 13a -16 or 15d -16 Under the Securities Exchange Act of 1934

For the Month of August 2025

Commission File Number: 001 -41084

_____

NeuroSense Therapeutics Ltd. (Translation of registrant’s name into English)

_____

NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672562 Israel +972-9- 7996183 (Address of principal executive offices)

_____

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20 -F or Form 40 -F .

Form 20 -F ☒ Form 40 -F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Attached hereto and incorporated herein by reference are the following exhibits:

Exhibit 99.1	Notice and Proxy Statement for the Annual General Meeting of Shareholders of the registrant scheduled for September 25, 2025
Exhibit 99.2	Proxy Card

This Report on Form 6 -K is hereby incorporated by reference into registrant’s Registration Statements on Form S -8 (File No. 333 -262480 ) and Form F -3 (File No. 333 -269306 , 333 -260338 , 333 -283656 and 333 -284051 ), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

/s/ Alon Ben-Noon
Alon Ben -Noon
Chief Executive Officer

2